D espite significant advancements in vascular medicine, including percutaneous interventional strategies, surgical revascularization remains the best available treatment option for many patients with coronary artery disease. Autologous saphenous vein grafts are still commonly used for coronary artery bypass grafting, especially for multivessel disease, when available arterial grafts are insufficient. However, saphenous vein graft patency is 61% at 10 years and only 50% at 15 years and more, significantly lower than for internal mammary artery grafts. 1, 2 Thus, in clinical medicine, saphenous vein graft failure remains a major clinical problem.
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The underlying pathophysiology of venous graft disease and late bypass failure includes intimal hyperplasia and subsequent accelerated atherosclerosis. 3 More than 100 years ago, Alexis Carrel, MD, who won the Nobel Prize in recognition of his work on vascular suture and the transplantation of blood vessels and organs, made the first observations of intimal hyperplasia after vein grafting; these findings were later linked to vein graft stenosis and failure. 4, 5 Furthermore, vein grafts implanted in the arterial circulation developed intimal hyperplasia, whereas those implanted in the venous circulation did not. 6 Although these observations were made decades ago, the molecular mechanisms of vein graft intimal hyperplasia remain subject to intense research given the clinical importance of graft failure. Because vascular smooth muscle cell (VSMC) proliferation plays a key role in the pathophysiology of intimal hyperplasia, 3, 7 it is of particular interest that pulsatile stretch leads to VSMC proliferation in saphenous veins but not in internal mammary arteries. 8 The process of converting mechanical forces into biochemical signals and the subsequent effect on cellular function has been termed "mechanotransduction." 9 Fluid shear stress, the frictional force per unit area from flowing blood, acts on the endothelial cells that line the vessels. Blood pressure, which drives fluid flow, causes circumferential stress on both endothelial cells and the VSMCs that surround the endothelium in arteries. 9 Both shear stress and circumferential stress are markedly increased in the arterial system compared with the venous system; they contribute to the development of intimal hyperplasia in vein grafts.
In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, new insight into the biology of vascular mechanotransduction is presented. In their study, Wu and coworkers 10 investigated the transcriptional regulation of insulin-like growth factor-1 receptor (IGF-1R) by the early growth response-1 (Egr-1) transcription factor. IGF-1 is a growth factor that participates in multiple physiological and pathophysiological pathways, including cellular growth and atherosclerosis. [11] [12] [13] IGF-1 promotes VSMC migration and proliferation. 14, 15 Furthermore, both IGF-1 secretion and IGF-1R expression are increased by mechanical stretch in VSMCs. 16, 17 Egr-1 is a mechanosensitive transcription factor known to participate in multiple cardiovascular pathological processes, such as atherosclerosis and intimal thickening. 18 Egr-1 expression, like IGF-1 and IGF-1R expression, is increased by mechanical stretch in many cell types. 19 Furthermore, it has been shown that stretch-inducible expression of the angiogenic factor CCN 1 (CYR61 [cysteine-rich angiogenic inducer 61], CTGF [connective tissue growth factor], NOV [nephroblastoma overexpressed]) in VSMCs is regulated by Egr-1. 20 In their study, the authors confirmed that mechanical stretch increases both mRNA and protein expression of Egr-1 in VSMCs. Using an Egr-1-knockout mouse, the authors then showed that Egr-1 deficiency attenuates the increase in IGF-1R expression and the proliferation of VSMCs subjected to mechanical stretch. Furthermore, intimal hyperplasia was suppressed in vein grafts obtained from Egr-1-knockout mice, and mechanical stretch led to nuclear translocation of Egr-1 in VSMCs of vein grafts. Both electrophoretic mobility shift assays and chromosome immunoprecipitation confirmed binding of Egr-1 to the IGF-1R promoter. To explore the mechanical stretch-responsive regulation of IGF-1R, deletion analysis of the IGF-1R promoter was performed, and the mechanical stretch-responsive region is located between nucleotides Ϫ270 and Ϫ130 of the IGF-1R promoter. Further site-specific mutagenesis analysis showed that 2 regions (Ϫ170/Ϫ150 and Ϫ210/Ϫ190) of the IGF-1R promoter are necessary for mechanical stretch-induced transcriptional activity; both of these regions contain an Egr-1 binding site.
Although Carrel made the first observations regarding intimal hyperplasia more than a century ago, the underlying pathophysiological processes remain incompletely defined and clinically important for hundreds of thousands of patients. The Egr-1/ IGF-1R interaction described in this issue represents a novel mechanotransduction pathway, and the results of this study lead us further down the road to understanding why vein grafts develop accelerated athero-sclerosis in the arterial system (Figure) . This study also raises new questions. Are there other regulators of IGF-1R transcription? Mechanical stretch-induced expression of IGF-1R was not completely normalized by genetic deletion of Egr-1. Therefore, it is likely that there are other mechanical stretchinduced transcription factors that control the IGF-1R promoter. How do upstream regulators of Egr-1, such as fibroblast growth factor 2, the mitogen-activated protein kinase (MEK)/ extracellular signal regulated kinase pathway, 18 or c-Jun, 21 affect regulation of the IGF-1R promoter? An important, yet unanswered, question concerns the receptors that transduce mechanical forces into biochemical signals. What are those "mechanosensors" and how are they linked to these pathways? Finally, how can the results of this study in mice be translated into meaningful therapeutic approaches to vein graft failure in patients undergoing bypass surgery? Hopefully, future research will point us in new directions that will allow vein grafts to function more like internal mammary artery grafts.
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Figure.
Implantation of a vein graft exposes VSMCs to mechanical stretch. Through activation of the Egr-1 transcription factor, IGF-1R transcription is upregulated. In combination with IGF-1, this leads to increased VSMC proliferation, intimal hyperplasia, and eventually vein graft failure. FGF indicates fibroblast growth factor.
